NCT00004982

Combination Iron Chelation Therapy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: —
• Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
• Sex: All
• Age: 7 Years
• Healthy volunteers: Not accepted

Summary

Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.

Conditions

• Iron Overload
• Thalassemia

Interventions

Type	Name	Description
DRUG	Combination Iron Chelation Therapy

Timeline

• Start date: 1998-12-01
• Completion: 2002-11-01
• First posted: 2000-03-14
• Last updated: 2010-01-14

Locations

1 site across 1 country: United States